文献速递淋巴瘤

利妥昔单抗治疗晚期无症状非巨块型滤泡性淋巴瘤的生活质量较观察等待显著改善

Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.
PubMed 文献 · Br J Haematol · 2024-11-27

这项国际随机3期试验比较观察等待、利妥昔单抗诱导及诱导后维持对无症状晚期滤泡性淋巴瘤患者生活质量的影响。长期结果显示,维持组在情绪健康(第37个月,p=0.0078)和掌控感(第25个月,p=0.0004;第37个月,p=0.0476)方面优于观察等待组。

要点

  • 维持组第37个月情绪健康改善优于观察等待组(p=0.0078)。
  • 维持组第25个月和第37个月掌控感显著优于观察等待组(p=0.0004;p=0.0476)。
  • 观察等待组更倾向回避思考疾病、认为学习疾病知识无帮助并对就诊赋予不愉快联想。

核心结论

  • 利妥昔单抗诱导和维持组生活质量评分改善,表明利妥昔单抗对生活质量无害,并在某些领域改善生活质量。

研究设计与样本

  • 国际随机3期「观察等待」试验,患者随机分为观察等待组(A组)、利妥昔单抗诱导组(B组)或利妥昔单抗诱导后维持组(C组)。
  • 生活质量分析纳入A组180例、C组188例,以及B组82例与同期随机至A组81例和C组84例的探索性分析。

主要发现

  • C组第37个月情绪健康改善优于观察等待组(p=0.0078)。
  • C组第25个月(p=0.0004)和第37个月(p=0.0476)感觉掌控自身情况的可能性显著高于观察等待组。
  • 观察等待组第7个月(p=0.0032)、第13个月(p=0.0015)和第25个月(p=0.0104)更可能回避思考疾病、认为学习疾病知识无帮助并对就诊赋予不愉快联想。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditionally, patients with asymptomatic, advanced-stage follicular lymphoma were managed with a watchful-waiting approach until disease progression. The 'Watch and Wait' Phase-3 randomised international trial examined whether rituximab could delay the need for treatment and the effect on quality of life (QoL). In this article, we present the long-term results of the QoL aspect of the trial. Patients were randomised to watchful-waiting (Arm A), rituximab induction (Arm B) or rituximab induction followed by maintenance (Arm C). We present the QoL outcomes from 180 patients (Arm A), 188 patients (Arm C) and an exploratory analysis of 82 (Arm B) compared to 81 and 84 patients concurrently randomised to arms A and C. Arm C reported greater improvement in emotional well-being overtime (Month 37, p = 0.0078) and were significantly more likely to feel in control of their situation than watchful-waiting patients (Month 25, p = 0.0004; Month 37, p = 0.0476). Watchful-waiting patients were significantly more likely to avoid thinking about their illness, did not find learning about their illness helped them and were more likely to attach unpleasant connotations to clinic visits (Month 7, p = 0.0032; Month 13, p = 0.0015; Month 25, p = 0.0104). These results demonstrate improved QoL scores in the induction and maintenance rituximab arm, indicating that rituximab was not detrimental to QoL and resulted in an improved QoL in some domains.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Marzolini MAV, Qian W, Clifton-Hadley L, et al. Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting. Br J Haematol. 2024. PMID: 39604791. doi:10.1111/bjh.19918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。